Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boric Acid Vaginal Inserts for Vulvovaginal Candidiasis
NCT07109869Phase 3Completed
- Sponsor
- pH-D Feminine Health
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of boric acid in vulvovaginal candidiasis (VVC) (3 arms), sponsored by pH-D Feminine Health. Primary endpoint: Proportion of patients with the absence of all signs and symptoms of vulvovaginal candidiasis at 28 days. Started Aug 2025; status: completed.
02
Drugs
boric acid
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT07109869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109869.